RNA interference in research and therapy of renal diseases

Contributions to Nephrology

Volumn 159, Issue , 2008, Pages 78-95

  Racz Z ^a   Hamar, P ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; MESSENGER RNA; OLIGONUCLEOTIDE; RNA;

ARTICLE; CHEMISTRY; GENE EXPRESSION REGULATION; GENE SILENCING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; KIDNEY DISEASE; KIDNEY TUMOR; KINETICS; METHODOLOGY; PROTEIN SYNTHESIS; RNA INTERFERENCE; VIRUS; VON HIPPEL LINDAU DISEASE;

GENE EXPRESSION REGULATION; GENE SILENCING; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; KIDNEY DISEASES; KIDNEY NEOPLASMS; KINETICS; OLIGONUCLEOTIDES; PROTEIN BIOSYNTHESIS; RNA; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VIRUSES; VON HIPPEL-LINDAU DISEASE;

EID: 48549107361     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000125587     Document Type: Review

References (30)

1. http://www.clinicaltrials.gov/ct/action/GetStudy
2. Napoli C, Lemieux C, Jorgensen R: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990;2:279-289.
3. Grishok A, Mello CC: RNAi (nematodes. Ceanorhabditis elegans). Adv Genet 2002;46:339-360.
4. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nt RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
5. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999;13:3191-3197.
6. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002;296:1000-1004.
7. Bartlett DW, Davis ME: Insights of the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2005;34:322-333.
8. Lim LP, Lau NP, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP: The microRNAs of Caenorhabditis elegans. Genes Dev 2003;17:991-1008.
9. Yang M, Li Y, Padgett RW: Micro RNAs: small regulators with big impact. Cytokine Growth Factor 2005;16:387-393.
10. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149.
11. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxshoorn D, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-717.
12. Racz Z, Hamar P: Can siRNA technology provide the tools for gene therapy of the future? Curr Med Chem 2006;13:2299-2230.
13. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:356-358.
14. Hamar P, Song E, Kökény G, Chen A, Ouyang N, Lieberman J: Small interfering RNA targeting Fas protects mice from renal ischemia-reperfusion injury. PNAS 2004;101:14883-14888.
15. Jackson AL, Bartz SR, Schelter J, Kobayshi SV, Burchard J, Mao M, Li B, Caret G, Linsey PS: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-637.
16. Semizarov D, Frost L, Sparthy A, Kroeger P, Halbert DN, Fesik SW: Specificity of short interfering RNA determined through gene expression signatures. PNAS 2003;100:6347-6352.
17. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG: Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-839.
18. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRN A. Nat Biotechnol 2005;23:457-462.
19. Meri S, Pangburn MK: Discrimination between activators and nonactivators of the alternative pathway of the complement regultion via a sialic acid/polyanion binding site on factor H. PNAS USA 1990;87:3982-3986.
20. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ: Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action. Pharmacology 1997;281:810-816.
21. Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid UN: Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res 2002;8:3611-3621.
22. Heidel JD, Yu Z, Liu JYC, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. PNAS 2007;104:5715-5721.
23. John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, Stoffel M, Langer R, Anderson DG, Horton JD, Koteliansky V, Bumcrot D: Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature Lett 2007;449:745-748.
24. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-541.
25. Narvaiza I, Aparicio O, Vera M, Razquin N, Bortolanza S, Prieto J, Fortes P: Effect of adenovirusmediated RNA interference on endogenous miRNAs in a mouse model of multidrog resistance protein 2 gene silencing. J Virol 2006;80:12236-12247.
26. Zhang S, Zhao B, Jiang H, Wang B, Ma B: Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007;123:1-10.
27. Dallas A, Vlassov AV: RNAi a novel antisense technology and its therapeutical potentail. Med Sci Monit 2006;12:RA67-RA74.
28. Du C, Wang S, Diao H, Guan Q, Zhong R, Jevnikar AM: Increasing resistance of tubular epithelial cells to apoptosis by shRNA therapy ameliorates ischaemia-reperfusion injury. Am J Transplant 2006;6:2256-2267.
29. Zender L, Hütker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Walthemathe M, Gösling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kühnel P, Kubicka S: Caspase 8 small interfering RNA prevents acute liver failure in mice. PNAS USA 2003;100:7797-7802.
30. Goruppi S, Bonventre JV, Kyriakis JM: Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 2002;21:5427-5436.